# Patent

## Title
Antithrombic peptides

## Abstract

This application is a continuation of Ser. No. 08/070,161, filed May 28, 1993, now abandoned.

## Background
The present invention relates to novel hydroxamate inhibitors of endothelin converting enzyme useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. More particularly, the novel compounds of the present invention are inhibitors of endothelin converting enzyme useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction, metabolic, endocrinological, and neurological disorders, congestire heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, restenosis, angina, ischemic disease, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease, cerebral vasospasm, and diabetes.

Endothelin-1 (ET-1), a potent vasoconstrictor, is a 21 amino acid bicyclic peptide that was first isolated from cultured porcine aortic endothelial cells. Endothelin-1, is one of a family of structurally similar bicyclic peptides which include; ET-2, ET-3, vasoactive intestinal contractor (VIC), and the sarafotoxins (SRTXs). The unique bicyclic structure and corresponding arrangement of the disulfide bridges of ET-1, which are the same for the endothelins, VIC, and the sarafotoxins, has led to significant speculation as to the importance of the resulting induced secondary structure to receptor binding and functional activity. ET-1 analogs with incorrect disulfide pairings exhibit at least 100-fold less vasoconstrictor activity.

Endothelin-1 is generated from a 203 amino acid peptide known as preproendothelin by an unknown dibasic endopeptidase. This enzyme cleaves the prepropeptide to a 38 (human) or 39 (porcine) amino acid peptide known as big endothelin or proendothelin. Big ET is then cleaved by an enzyme, known as endothelin converting enzyme or ECE, to afford the biologically active molecule ET-1. Big ET is only 1% as potent as ET-1 in inducing contractile activity in vascular strips but it is equally potent in vivo at raising blood pressure, presumably by rapid conversion to ET-1 (Kimura S, Kasuya Y, Sawamura T, et al, "Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: Structure-activity relationship of big endothelin-1," J. Cardiovasc Pharmacol 1989;13:S5). There have been numerous reports describing possible proteases in both the cytoplasm and membrane bound cellular fractions of endothelial cells (Ikegawa R, Matsumura Y, Takaoka M, et al, "Evidence for pepstatin-sensitive conversion of porcine big endothelin-1 to endothelin-1 by the endothelial cell extract," Biochem Biophys Res Commun 1990;167:860; Sawamura T, Kimura S, Shinmi O, et al, "Characterization of endothelin converting enzyme activities in soluble fraction of bovine cultured endothelial cells," Biochem Biophys Res Commun 1990;169:1138; Sawamura T, Shinmi O, Kishi N, et al, "Analysis of big endothelin-1 digestion by cathepsin D." Biochem Biophys Res Commun 1990;172:883; Shields P P, Gonzales T A, Charles D, et al, "Accumulation of pepstatin in cultured endothelial cells and its effect on endothelin processing," Biochem Biophys Res Commun 1991;177:1006; Matsumura Y, Ikegawa R, Tsukahara Y, et al, "Conversion of big endothelin-1 to endothelin-1 by two types of metalloproteinases derived from porcine aortic endothelial cells," FEBS Lett, 1990;272:166; Sawamura T, Kasuya Y, Matsushita S N, et al, "Phosphoramidon inhibits the intracellular conversion of big endothelin-1 to endothelin-1 in cultured endothelial cells," Biochem Biophys Res Commun 1991;174:779; Takada J, Okada K, Ikenaga T, et al, "Phosphoramidon-sensitive endothelin-converting enzyme in the cytosol of cultured bovine endothelial cells," Biochem Biophys Res Commun 1991;176:860; Ahn K, Beningo K, Olds G, Hupe D, "Endothelin-converting enzyme from bovine and human endothelial cells," J Vasc Res 1991;29:76, 2nd International symposium on endothelium-derived vasoactive factors). Many groups have chosen to isolate ECE from endothelial cells of various species, since endothelin is known to be synthesized and secreted by this cell type. It was initially reported that two types of protease activity were present in porcine or bovine endothelial cells that could cause conversion of big ET to ET in vitro (Ikegawa R, supra; Sawamura T, supra; Matsumura Y, supra; Takada J, supra; Ahn K, supra). However, it was subsequently found that the aspartic protease activity from porcine endothelial cells, thought to be predominantly cathepsin D, also caused further degradation of ET-1 and was therefore unlikely to be the true ECE (Sawamura T, supra). Moreover, human cathepsin D also causes rapid degradation of ET-1. In addition, there has been one study showing that the intracellular accumulation of pepstatin, an aspartic protease inhibitor, did not inhibit ET-1 production in cultured bovine aortic endothelial cells (Shields P P, supra). Stronger evidence that ECE is in fact a neutral metalloprotease has appeared (Matsumura Y, supra; Sawarnura T, supra; Takada J, supra; Ahn K, supra), although to date there have been no known specific metalloprotease ECE inhibitors to confirm these findings in vivo. However, the nonspecific metalloproteinase inhibitor, phosphoramidon, has been shown to inhibit the intracellular conversion of big ET-1 to ET-1 in cultured vascular endothelial cells and smooth muscle cells (Sawamura T, supra).

ET-converting activity has been detected in both the membranous and cytosolic fractions of cultured porcine, bovine, and human endothelial cells (Matsumura Y, supra). Micromolar concentrations of phosphoramidon have been shown to block the pressor response of big ET both in vitro and in vivo (Takada J, supra; Fukuroda T, Noguchi K, Tsuchida S, et al, "Inhibition of biological actions of big endothelin-1 by phosphoramidon," Biochem Biophys Res Commun 1990;172:390; Matsumura Y, Hisaki K, Takaoka M, Morimoto S, "Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1," Eur J Pharmacol 1990;185:103; McMahon E G, Palomo M A, Moore W M, et al, "Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro," Proc Natl Acad Sci USA 1991;88:703). It has recently been reported that phosphoramidon is able to inhibit vasoconstrictor effects evokedby intravenous injections of big ET-1 in anaesthetized pigs, but did not have any effect on the plasma ET-1 level (Modin A, Pernow J, Lundberg J M, "Phosphoramidon inhibits the vasoconstrictor effects evoked bybig endothelin-1 but not the elevation of plasma endothelin-1 in vivo," Life Sci 1991;49:1619). It should be noted that phosphoramidon is a rather general metalloproteinase inhibitor and clearly the discovery of specific ECE inhibitors such as those described in the present invention is important.

Endothelin is involved in many human disease states.

Several in vivo studies with ET antibodies have been reported in disease models. Left coronary artery ligation and reperfusion to induce myocardial infarction in the rat heart, caused a four- to seven-fold increase in endogenous endothelin levels. Administration of ET antibody was reported to reduce the size of the infarction in a dose-dependent manner (Watanabe T, et al, "Endothelin in Myocardial Infarction," Nature (Lond.) 1990;344:114). Thus, ET may be involved in the pathogenesis of congestire heart failure and myocardial ischemia (Marguiles K B, et al, "Increased Endothelin in Experimental Heart Failure," Circulation 1990;82:2226).

Studies by Kon and colleagues using anti-ET antibodies in an ischemic kidney model, to deactivate endogenous ET, indicated the peptide's involvement in acute renal ischemic injury (Kon V, et al, "Glomerular Actions of Endothelin In Vivo," J Clin Invest 1989;83:1762). In isolated kidneys, preexposed to specific antiendothelin antibody and then challenged with cyclosporine, the renal perfusate flow and glomerular filtration rate increased, while renal resistance decreased as compared with isolated kidneys preexposed to a nonimmunized rabbit serum. The effectiveness and specificity of the anti-ET antibody were confirmed by its capacity to prevent renal deterioration caused by a single bolus dose (150 pmol) of synthetic ET, but not by infusion of angiotensin II, norepinephrine, or the thromboxane A.sub.2 mimetic U-46619 in isolated kidneys (Perico N, et al, "Endothelin Mediates the Renal Vasoconstriction Induced by Cyclosporine in the Rat," J Am Soc Nephrol 1990;1:76).

Others have reported inhibition of ET-1 or ET-2-induced vasoconstriction in rat isolated thoracic aorta using a monoclonal antibody to ET-1 (Koshi T, et al, "Inhibition of Endothelin (ET)-1 and ET-2-Induced Vasoconstriction by Anti-ET-1 Monoclonal Antibody," Chem Pharm Bull 1991;39:1295).

Combined administration of ET-1 and ET-1 antibody to rabbits showed significant inhibition of the blood pressure and renal blood flow responses (Miyamori I, et al, Systemic and Regional Effects of Endothelin in Rabbits: Effects of Endothelin Antibody," Clin Exp Pharmacol Physiol 1990;17:691).

Other investigators have reported that infusion of ET-specific antibodies into spontaneously hypertensive rats (SHR) decreased mean arterial pressure (MAP), and increased glomerular filtration rate and renal blood flow. In the control study with normotensive Wistar-Kyoto rats (WKY), there were no significant changes in these parameters (Ohno A, "Effects of Endothelin-Specific Antibodies and Endothelin in Spontaneously Hypertensive Rats," J Tokyo Women's Med Coll 1991;61:951).

In addition, elevated levels of endothelin have been reported in several disease states (see Table I below). ______________________________________ Plasma Concentrations of ET-1 in Humans ET Plasma Normal      Levels Reported Condition       Condition   (pg/mL) ______________________________________ Atherosclerosis 1.4             3.1   pmol/L Surgical operation 1.5             7.3 Buerger's disease 1.6             4.8 Takayasu's arteries 1.6             5.3 Cardiogenic shock 0.3             3.7 Congestive heart failure (CHF) 9.7             20.4 Mild CHF        7.1             11.1 Severe CHF      7.1             13.8 Dilated cardiomyopathy 1.6             7.1 Preeclampsia    10.4   pmol/L   22.6  pmol/L Pulmonary hypertension 1.45            3.5 Acute myocardial infarction 1.5             3.3 (several reports) 6.0             11.0 0.76            4.95 0.50            3.8 Subarachnoid hemorrhage 0.4             2.2 Crohn's disease 0-24   Fmol/mg  4-64  Fmol/mg Ulcerative colitis 0-24   Fmol/mg  20-50 Fmol/mg Cold pressor test 1.2             8.4 Raynaud's phenomenon 1.7             5.3 Raynaud's/hand cooling 2.8             5.0 Hemodialysis    <7              10.9 (several reports) 1.88            4.59 Chronic renal failure 1.88            10.1 Acute renal failure 1.5             10.4 Uremia before hemodialysis 0.96            1.49 Uremia after hemodialysis 0.96            2.19 Essential hypertension 18.5            33.9 Sepsis syndrome 6.1             19.9 Postoperative cardiac 6.1             11.9 Inflammatory arthritides 1.5             4.2 Malignant       4.3             16.2 hemangioendothelioma (after removal) ______________________________________

Burnett and co-workers recently demonstrated that exogenous infusion of ET (2.5 ng/kg/mL) to anesthetized dogs, producing a doubling of the circulating concentration, did have biological actions (Lerman A, et al, "Endothelin Has Biological Actions at Pathophysiological Concentrations," Circulation 1991;83:1808). Thus heart rate and cardiac output decreased in association with increased renal and systemic vascular resistances and antinatriuresis. These studies support a role for endothelin in the regulation of cardiovascular, renal, and endocrine function.

In the anesthetized dog with congestive heart failure, a significant two- to three-fold elevation of circulating ET levels has been reported (Cavero P G, et al, "Endothelin in Experimental Congestive Heart Failure in the Anesthetized Dog," Am J Physiol 1990;259:F312), and studies in humans have shown similar increases (Rodeheffer R J, et al, "Circulating Plasma Endothelin Correlates With the Severity of Congestire Heart Failure in Humans," Am J Hypertension 1991;4:9A). When ET was chronically infused into male rats, to determine whether a long-term increase in circulating ET levels would cause a sustained elevation in mean arterial blood pressure, significant, sustained, and dose-dependent increases in mean arterial blood pressure were observed. Similar results were observed with ET-3 although larger doses were required (Mortenson L H, et al, "Chronic Hypertension Produced by Infusion of Endothelin in Rats," Hypertension 1990;15:729). Recently the nonpeptide endothelin antagonist RO 46-2005 has been reported to be effective in models of acute renal ischemia and subarachnoid hemorrhage in rats (3rd International Conference on Endothelin, Houston, Tex., February 1993). In addition, the ET.sub.A antagonist BQ-153 has also been shown to prevent early cerebral vasospasm following subarachnoid hemorrhage after intracisternal injection (Clozel M, et al, Life Sciences 1993;52:825); to prevent blood pressure increases in stroke-prone spontaneously hypertensive rats (Nishikibe M, et al, Life Sciences 1993;52:717); and to attenuate the renal vascular effects of ET-1 in anaesthetized pigs (Cirino M, et al, J Pharm Pharmacol 1992;44:782).

The distribution of the two cloned receptor subtypes, termed ET.sub.A and ET.sub.B, have been studied extensively (Arai H, et al, Nature 1990;348:730; Sakurai T, et al, Nature 1990;348:732). The ET.sub.A, or vascular smooth muscle receptor, is widely distributed in cardiovascular tissues and in certain regions of the brain (Lin HY, et al, Proc Natl Acad Sci 1991;88:3185). The ET.sub.B receptor, originally cloned from rat lung, has been found in rat cerebellum and in endothelial cells, although it is not known if the ET.sub.B receptors are the same from these sources. The human ET receptor subtypes have been cloned and expressed (Sakamoto A, et al, Biochem Biophys Res Chem 1991;178:656; Hosoda K, et al, FEBS Lett 1991;287:23). The ET.sub.A receptor clearly mediates vasoconstriction and there have been a few reports implicating the ET.sub.B receptor in the initial vasodilatory response to ET (Takayanagi R, et al, FEBS Lett 1991;282:103). However, recent data has shown that the ET.sub.B receptor can also mediate vasoconstriction in some tissue beds (Panek R L, et al, Biochem Biophys Res Commun 1992;183(2):566).

Plasma endothelin-1 levels were dramatically increased in a patient with malignant hemangio-endothelioma (Nakagawa K, et al, Nippon Hifuka Gakkai Zasshi 1990;100:1453).

The ET receptor antagonist BQ-123 has been shown to block ET-1-induced bronchoconstriction and tracheal smooth muscle contraction in allergic sheep providing evidence for expected efficacy in bronchopulmonary diseases such as asthma (Noguchi, et al, Am Rev Respir Dis 1992;145(4 Part 2):A858).

Circulating endothelin levels are elevated in women with preeclampsia and correlate closely with serum uric acid levels and measures of renal dysfunction. These observations indicate a role for ET in renal constriction in preeclampsia (Clark B A, et al, Am J Obstet Gynecol 1992;166:962).

Plasma immunoreactive endothelin-1 concentrations are elevated in patients with sepsis and correlate with the degree of illness and depression of cardiac output (Pittett J, et al, Ann Surg 1991;213(3):261).

In addition, the ET-1 antagonist BQ-123 has been evaluated in a mouse model of endotoxic shock. This ET.sub.A antagonist significantly increased the survival rate in this model (Toshiaki M, et al, 20.12.90. EP 0 436 189 A1).

Endothelin is a potent agonist in the liver eliciting both sustained vasoconstriction of the hepatic vasculature and a significant increase in hepatic glucose output (Gandhi C B, et al, J of Biolog Chem 1990;265(29):17432).In streptozotocin-diabetic rats, there is an increased sensitivity to endothelin-1 (Tammesild P J, et al, Clin Exp Pharmacol Physiol 1992;19(4):261). In addition, increased levels of plasma ET-1 have been observed in microalbuminuric insulin-dependent diabetes mellitus patients indicating a role for ET in endocrine disorders such as diabetes (Collier A, et al, Diabetes Care 1992;15(8):1038).

ET.sub.A antagonist receptor blockade has been found to produce an antihypertensive effect in normal to low renin models of hypertension with a time course similar to the inhibition of ET-1 pressor responses (Basil M K, et al, J Hypertension 1992;10(Suppl 4):S49). The endothelins have been shown to be arrhythmogenic, and to have positive chronotropic and inotropic effects, thus ET receptor blockade would be expected to be useful in arrhythmia and other cardiovascular disorders (Hah S-P, et al, Life Sci 1990;46:767).

The widespread localization of the endothelins and their receptors in the central nervous system and cerebrovascular circulation has been described (Nikolov R K, et al, Drugs of Today 1992;28(5):303). Intracerebroventricular administration of ET-1 in rats has been shown to evoke several behavioral effects. These factors strongly suggest a role for the ETs in neurological disorders. The potent vasoconstrictor action of ETs on isolated cerebral arterioles suggests the importance of these peptides in the regulation of cerebrovascular tone. Increased ET levels have been reported in some CNS disorders, ie, in the CSF of patients with subarachnoid hemorrhage and in the plasma of women with preeclampsia. Stimulation with ET-3 under conditions of hypoglycemia have been shown to accelerate the development of striatal damage as a result of an influx of extracellular calcium. Circulating or locally produced ET has been suggested to contribute to regulation of brain fluid balance through effects on the choroid plexus and CSF production. ET-1-induced lesion development in a new model of local ischemia in the brain has been described.

Circulating and tissue endothelin immunoreactivity is increased more than two-fold in patients with advanced atherosclerosis (Lerman A, et al, New England J Med 1991;325:997). Increased endothelin immunoreactivity has also been associated with Buerger's disease (Kanno K, et al, J Amer Med Assoc 1990;264 2868) and Raynaud's phenomenon (Zamora M R, et al, Lancet 1990;336:1144). Likewise, increased endothelin concentrations were observed in hyper-cholesterolemic rats (Horio T, et al, Atherosclerosis 1991;89:239).

An increase of circulating endothelin levels was observed in patients that underwent percutaneous transluminal coronary angioplasty (PTCA) (Tahara A, et al, Metab Clin Exp 1991;40:1235; Sanjay K, et al, Circulation 1991;84(Suppl. 4):726).

Increased plasma levels of endothelin have been measured in rats (Stelzner T J, et al, Am J Physiol 1992;262:L614) and humans (Miyauchi T, et al, Jpn J Pharmacol 1992;58:279P; Stewart D J, et al, Ann Internal Medicine 1991;114:464) with pulmonary hypertension.

Elevated levels of endothelin have also been measured in patients suffering from ischemic heart disease (Yasuda M, et al, Amer Heart J 1990;119:801; Ray S G, et al, Br Heart J 1992;67:383) and either stable or Unstable angina (Stewart J T, et al, Br Heart J 1991;66:7).

Infusion of an endothelin antibody 1 hour prior to and 1 hour after a 60-minute period of renal ischaemia resulted in changes in renal function versus control. In addition, an increase in glomerular platelet-activating factor was attributed to endothelin (Lopez-Farre A, et al, J Physiology 1991;444:513-). In patients with chronic renal failure as well as in patients on regular hemodialysis treatment mean plasma endothelin levels were significantly increased (Stockenhuber F, et al, Clin Sci (Lond.) 1992;82:255). In addition, it has been suggested that the proliferative effect of endothelin on mesangial cells may be a contributing factor in chronic renal failure (Schultz P J, J Lab Clin Med 1992;119:448).

Local intra-arterial administration of endothelin has been shown to induce small intestinal mucosal damage in rats in a dose-dependent manner (Mirua S, et al, Digestion 1991;48:163). Administration of endothelin-1 in the range of 50-500 pmol/kg into the left gastric artery increased the tissue type plasminogen activator release and platelet activating formation and induced gastric mucosal hemorrhagic change in a dose-dependent manner (Kurose I, et al, Gut 1992;33:868). Furthermore, it has been shown that an anti-ET-1 antibody reduced ethanol-induced vasoconstriction in a concentration-dependent manner (Masuda E, et al, Am J Physiol 1992;262:G785). Elevated endothelin levels have been observed in patients suffering from Crohn's disease and ulcerative coliris (Murch S R, et al, Lancet 1992;339:381).

Japanese Published Patent Application JP 04041430-A, published Feb. 12, 1992, disclosed phosphoramidon as an endothelin converting enzyme inhibitor.

PCT International Published Patent Application WO 92/12170, published Jul. 23, 1992, discloses peptides of up to 20 amino acids including pentapeptides of the formula:

wherein A.sub.3 and A.sub.3.sup.1 independently represent Ser, Gly, Asp, or Asn and A.sub.4 and A.sub.4.sup.1 independently represent Val, Pro, Gly, or Ala and A.sub.5 represents Asp or Asn. The peptides are disclosed to be inhibitors of endothelin formation.

PCT International Published Patent Application WO 92/01468, published Feb. 16, 1992, discloses compounds of the formula: ##STR1## wherein A.sub.1, A.sub.2 is an amino acid;

X is OH or a monosaccharide residue;

R.sub.1 is OH, alkyl, alkoxy, allyl, or NR.sub.2 R.sub.3,

The compounds are disclosed as agents for inhibiting endothelin converting enzyme.

PCT International Published Patent Application WO 92/13545, published Aug. 20, 1992, discloses compounds of the formula (these compounds also are described in Shiosaki K, et al, Journal of Medicinal Chemistry 1993;36:468): ##STR2## wherein A is hydrogen, an N-protecting group or R.sub.1 NHCH(R.sub.2)C(O)-- wherein R.sub.1 is H or an N-protecting group and R.sub.2 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, carboxyalkyl, or alkoxycarbonylalkyl; or A is HO.sub.2 C(CH.sub.2).sub.n C(O)-- wherein n is one to 3;

B is --N(R.sub.4)CH(R.sub.3)C(O)-- wherein R.sub.4 is hydrogen or lower alkyl and R.sub.3 is lower alkyl, cycloalkyl, or cycloalkylalkyl;

C is --N(R.sub.5)CH(R.sub.6)C(O)-- wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl;

R is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, or bicyclic heterocyclic;

X is --CH.sub.2 -- or --C(O)--;

D is

(1) --OR.sub.7 wherein R.sub.7 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl;

(2) --NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently selected from hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, and --(CH.sub.2).sub.m --Z wherein m is two to eight and Z is --OH, heterocyclic, --SO.sub.3 H, --CO.sub.2 R.sub.10 wherein R.sub.10 is hydrogen or lower alkyl or Z is --NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, lower alkyl, cycloalkyl, and cycloalkylalkyl;

(3) --NHCH(R.sub.13)C(O)-- wherein R.sub.13 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl; or

(4) --NHCH(R.sub.13)C(O)NHCH(R.sub.14)C(O)-- wherein R.sub.13 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl and R.sub.14 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, cyanoalkyl, carboxyalkyl, or alkoxycarbonylalkyl; and

E is

(1) absent;

(2) --OR.sub.15 wherein R.sub.15 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl; or

(3) --NR.sub.16 R.sub.17 wherein R.sub.16 and R.sub.17 are independently selected from hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, and --(CH.sub.2).sub.p --Y wherein p is two to eight and Y is --OH, heterocyclic, --SO.sub.3 H, --CO.sub.2 R.sub.18 wherein R.sub.18 is hydrogen or lower alkyl or Y is --NR.sub.19 R.sub.20 wherein R.sub.19 and R.sub.20 are independently selected from hydrogen, lower alkyl, cycloalkyl, and cycloalkylalkyl; or a pharmaceutically acceptable salt, ester, or prodrug thereof; and compounds of the Formula II ##STR3## wherein A is hydrogen, an N-protecting group, R.sub.1 NHCH(R.sub.2)C(O)-- wherein R.sub.1 is H or an N-protecting group and R.sub.2 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, carboxyalkyl, or alkoxycarbonylalkyl; or A is HO.sub.2 C(CH.sub.2).sub.n C(O)-- wherein n is one to 3;

B is --N(R.sub.4)CH(R.sub.3)C(O)-- wherein R.sub.4 is hydrogen or lower alkyl and R.sub.3 is lower alkyl, cycloalkyl, or cycloalkyl-alkyl;

C is --N(R.sub.5)CH(R.sub.6)C(O)-- wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl;

R is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, or bicyclic heterocyclic;

P.sub.4 is hydrogen, lower alkyl, or benzyl;

X is --CH.sub.2 -- or --C(O)--;

D is

(1) --OR.sub.7 wherein R.sub.7 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl;

(2) --NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently selected from hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, and --(CH.sub.2).sub.m --Z wherein m is two to eight and Z is --OH, heterocyclic, --SO.sub.3 H, --CO.sub.2 R.sub.10 wherein R.sub.10 is hydrogen or lower alkyl or Z is --NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, lower alkyl, cycloalkyl, and cycloalkylalkyl;

(3) --NHCH(R.sub.13)C(O)-- wherein R.sub.13 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl; or

(4) --NHCH(R.sub.13)C(O)NHCH(R.sub.14)C(O)-- wherein R.sub.13 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl and R.sub.14 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, cyanoalkyl, carboxyalkyl, or alkoxycarbonylalkyl; and

E is

(1) absent;

(2) --OR.sub.15 wherein R.sub.15 is hydrogen, lower alkyl, cycloalkyl, or cycloalkylalkyl; or

(3) --NR.sub.16 R.sub.17 wherein R.sub.16 and R.sub.17 are independently selected from hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, and --(CH.sub.2).sub.p --Y wherein p is two to eight and Y is --OH, heterocyclic, --SO.sub.3 H, --CO.sub.2 R.sub.18 wherein R.sub.18 is hydrogen or lower alkyl or Y is --NR.sub.19 R.sub.20 wherein R.sub.19 and R.sub.20 are independently selected from hydrogen, lower alkyl, cycloalkyl, and cycloalkylalkyl; or a pharmaceutically acceptable salt, ester, or prodrug thereof; and compounds of the Formula III ##STR4## wherein A is hydrogen, an N-protecting group, R.sub.1 NHCH(R.sub.2)C(O)-- wherein R.sub.1 is H or an N-protecting group and R.sub.2 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, carboxyalkyl, or alkoxycarbonylalkyl, or arylalkoxycarbonylalkyl; or A is HO.sub.2 C(CH.sub.2).sub.n C(O)-- wherein n is one to 3; or A is R.sub.1a C(O)-- or R.sub.1a S(O).sub.2 -- wherein R.sub.1a is heterocyclic; or A is (aminoalkyl) (alkyl)aminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, (dialkylaminoalkyl)(alkyl)aminocarbonyl, (aminoalkyl) (alkyl)aminosulfonyl, (alkylaminoalkyl(alkyl)aminosulfonyl, (dialkylaminoalkyl)(alkyl)aminosulfonyl, (heterocyclicalkyl)(alkyl)aminocarbonyl, or (heterocyclicalkyl)(alkyl)aminosulfonyl;

B is --N(R.sub.4)CH(R.sub.3)C(O)-- wherein R.sub.4 is hydrogen or lower alkyl and R.sub.3 is lower alkyl, cycloalkyl, or cycloalkylalkyl;

C is --N(R.sub.5)CH(R.sub.6)C(O)-- wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is lower alkyl, cycloalkyl, or cycloalkylalkyl;

R is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, or bicyclic heterocyclic; and

R.sub.21 is lower alkyl, cycloalkyl, or cycloalkylalkyl; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

European Published Patent Application EP 0518299A2, published Dec. 16, 1992, discloses compounds of Formula I ##STR5## wherein R.sub.1, R.sub.2, and R.sub.3 each represent hydrocarbon groups which may be substituted, except cases in which (1) R.sub.2 is unsubstituted methyl, (2) R.sub.3 is an unsubstituted hydrocarbon group having one to three carbon atoms, and (3) R.sub.1 is benzyloxycarbonylamino-methyl, R.sub.2 is isobutyl, and R.sub.3 is isobutyl or phenylmethyl. The compounds were disclosed as having endothelin converting enzyme inhibiting activity.

Bertenshaw S R, et al, Journal of Medicinal Chemistry 1993;36:173 discloses compounds of the formula ##STR6## wherein X is CH.sub.2, NH, or O;

Japanese Published Patent Application 04327592A, published Nov. 17, 1992, discloses compounds of Formula I ##STR7##

A=leucine, isoleucine, or phenylalanine residue;

Trp=tryptophan residue;

R=lower alkyl, lower alkoxy, or halogen;

X=H or alkali metal;

Y=H, alkali metal, or lower alkyl;

m=0-3;

n=1-4.

R is n-propyl, OEt, Bn, or cyclohexylmethyl as inhibitors of endothelin converting enzyme. The enzyme used in the study was a phosphoramidon sensitive metalloprotease obtained from rabbit lung homogenate.

However, the compounds disclosed in JP 04041430-A, WO 92/12170, WO 92/01468, WO 92/13545, EP 0518299A2, and Journal of Medicinal Chemistry 1993;36:173 do not disclose or suggest the novel hydroxamate peptides of the present invention described hereinafter.

Accordingly, the present invention is a compound of Formula I ##STR8## wherein R is hydrogen, ##STR9## wherein R.sup.3 is hydrogen or ##STR10## wherein R.sup.4 is alkyl, aryl, or arylalkyl, and m is zero or an integer of one and ##STR11## wherein R.sup.5 is hydrogen or alkyl, and n is as defined above; ##STR12## wherein R.sup.6 is hydrogen or methyl, R.sup.7 is aryl or heteroaryl, and ##STR13## wherein R.sup.8 is hydrogen, alkyl, alkenyl, or cycloalkyl, and R.sup.6 and p are as defined above or ##STR14## wherein R.sup.9 is hydrogen, ##STR15## wherein R.sup.10 and R.sup.11 are each independently the same or different and each is hydrogen, alkyl, cycloalkyl or --(CH.sub.2).sub.q -aryl, wherein q is zero or an integer of one or two or ##STR16## wherein R.sup.10 is as defined above and R.sup.6 and p are as defined above or ##STR17## wherein R.sup.11 is hydrogen, alkyl, alkenyl, or cycloalkyl, and R.sup.6 and p are as defined above or one of ##STR18## wherein R.sup.6, R.sup.7, and p are as defined above; R.sup.1 is hydrogen or alkyl; AA.sup.5, or AA.sup.6 is L, D, or DL; or a pharmaceutically acceptable salt thereof.

Elevated levels of endothelin have been postulated to be involved in a number of pathophysiological states including diseases associated with the cardiovascular system as well as various metabolic and endocrinological disorders. As inhibitors of endothelin converting enzyme, the compounds of Formula I are useful in the treatment of hypertension, myocardial infarction, metabolic, endocrinological and neurological disorders, congestire heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, restenosis, angina, ischemic disease, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic diseases including Raynaud's disease, cerebral vasospasm, and diabetes.

A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I in unit dosage form in the treatment methods mentioned above.

Finally, the present invention is directed to methods for production of a compound of Formula I.

In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having from one to 12 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, dodecyl, and the like.

The term "alkenyl" means a straight or branched unsaturated hydrocarbon radical having from two to 12 carbon atoms and includes, for example, ethenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, 1-undecenyl, 1-dodecenyl, and the like.

The term "cycloalkyl" means a saturated hydrocarbon ring which contains from three to 12 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, and the like.

The terms "alkoxy" and "thioalkoxy" are O-alkyl or S-alkyl as defined above for alkyl.

The term "aryl" means an aromatic radical which is a phenyl group, a benzyl group, a naphthyl group, a biphenyl group, a pyrenyl group, an anthracenyl group, 3,3-diphenylalanyl, 10,11-dihydro-5H-dibenzo-[a,d]-(cyclohepten-5-yl)glycyl, or a fluorenyl group and the like, unsubstituted or substituted by one to four substituents selected from alkyl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy thiol nitro, halogen, amino; ##STR19## wherein alkyl is as defined above, ##STR20## wherein alkyl is as defined above, ##STR21## wherein alkyl is as defined above, or aryl.

The term "arylalkyl" means an aromatic radical attached to an alkyl radical wherein aryl and alkyl are as defined above, for example, benzyl, fluorenylmethyl, and the like.

The term "heteroaryl" means a heteroaromatlc radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7- indolyl, N-formyl- 2-, 3-, 4-, 5-, 6-, 7- indolyl, 2 -, 3 -, 4-, 5 -, 6 -, 7-benzo[b]thienyl, or 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl, unsubstituted or substituted by one to two substituents selected from alkyl as defined above, aryl as defined above, alkoxy as defined above, thioalkoxy as defined above, hydroxy, thiol, nitro, halogen, formyl, amino; ##STR22## wherein alkyl is as defined above, ##STR23## wherein alkyl is as defined above ##STR24## wherein alkyl is as defined above, or phenyl.

"Alkali metal" is a metal in Group IA of the periodic table and includes, for example, lithium, sodium, potassium, and the like.

"Alkaline-earth metal" is a metal in Group IIA of the periodic table and includes, for example, calcium, barium, strontium, and the like.

"Noble metal" is platinum, palladium, rhodium, ruthenium, and the like.

"Halogen" is fluorine, chlorine, bromine, or iodine.

The following table provides a list of abbreviations and definitions thereof used in the present invention. Abbreviation*  Amino Acid Ala            Alanine Arg            Arginine Asn            Asparagine Asp            Aspartic acid Cys            Cysteine Glu            Glutamic acid Gln            Glutamine Gly            Glycine His            Histidine Ile            Isoleucine Leu            Leucine Lys            Lysine Met            Methionine Phe            Phenylalanine Pro            Proline Ser            Serine Thr            Threonine Trp            Tryptophan Tyr            Tyrosine Val            Valine Abbreviation*  Modified and Unusual Amino Acid Nva            Norvaline Nle            Norleucine Alg            2-Amino-4-pentanoic acid (allylgycine) Cpn            2-Amino-3-cyclopropane propanoic acid (Cyclopropylalanine) Chx            Cyclohexylalanine (Hexahydrophenylalanine) His (Dnp)      N.sup.im -2,4-Dinitrophenyl - histidine HomoPhe        2-Amino-5-phenylpentanoic acid (homophenylalanine) 1-Nal          3-(1'-Naphthyl)alanine 2-Nal          3-(2'-Naphthyl)alanine Pgy            2-Aminopentanoic acid (Propylglycine) Pyr            2-Amino-3-(3-pyridyl)- propanoic acid (3-Pyridylalanine) Tza            2-Amino-3-(4-thiazolyl)- propanoic acid Tyr (Ot-Bu)    O-tertiary butyltyrosine Tyr (OMe)      O-methyltyrosine Tyr (OEt)      O-ethyltyrosine Trp (For)      N.sup.in -Formyltryptophan His (t-Bu)     N.sup.im -tertiary butylhistidine His (C.phi..sub.3) N.sup.im -triphenylmethyl- histidine (N.sup.im -tritylhistidine) Trp (Me)       N.sup.in -Methyltryptophan Asp (Ot-Bu)    Aspartic acid 4-tertiary butyl ester Asp (OMe)      Aspartic acid 4-methyl ester Asp (OBn)      Aspartic acid 4-benzyl ester Glu (Ot-Bu)    Glutamic acid 5-tertiary butyl ester Glu (OMe)      Glutamic acid 5-methyl ester Bta            3-Benzothienyl alanine Bfa            3-Benzofuranyl alanine Abbreviation   Protecting Group Ac             Acetyl Acm            Acetamidomethyl Ada            1-Adamantyl acetic acid Adoc           Adamantyloxycarbonyl CBZ            Benzyloxycarbonyl 2-Br-CBZ       ortho-Bromobenzyloxy- carbonyl 2-Cl-CBZ       ortho-Chlorobenzyloxy- carbonyl Bom            Benzyloxymethyl Boc            tertiary Butyloxycarbonyl TBS            tertiary Butyldimethyl- silyl Dnp            2,4-Dinitrophenyl For            Formyl Fmoc           9-Fluorenylmethyloxy- carbonyl NO.sub.2       Nitro Tos            4-Toluenesulfonyl (tosyl) Trt            Triphenylmethyl (trityl) Bn             Benzyl O-Bn           O-Benzyl O-Me           O-Methyl Ph             Phenyl Abbreviation   Solvents and Reagents HOAc           Acetic acid CH.sub.3 CN    Acetonitrile CH.sub.2 Cl.sub.2 or DCM Dichloromethane DCC            N,N'-Dicyclohexyl- carbodiimide DMAP           4-dimethylaminopyridine DIEA           N,N-Diisopropylethylamine DMF            Dimethylformamide HCl            Hydrochloric acid HF             Hydrofluoric acid HOBt           1-Hydroxybenzotriazole KOH            Potassium hydroxide TFA            Trifluoroacetic acid EDAC           Ethyl-3-(3-dimethylamino- propyl)carbodiimide hydrochloride NaHCO.sub.3    Sodium bicarbonate NaCl           Sodium chloride NaCNBH.sub.4   Sodium cyanoborohydride MgSO.sub.4     Magnesium sulfate LAH            Lithium aluminum hydride KHSO.sub.4     Potassium bisulfate MeOH           Methanol CHCl.sub.3     Chloroform TEA or Et.sub.3 N Triethylamine THF            Tetrahydrofuran EtOAc          Ethyl acetate N.sub.2        Nitrogen NaN.sub.3      Sodium azide DMSO           Dimethylsulfoxide EDTA           Ethylenediamine tetraacetic acid MBHA Resin     Methylbenzhydrylamine resin Sasrin Resin   2-methoxy-4-alkoxybenzyl alcohol resin ______________________________________ *If the optical activity of the amino acid is other than L (S), the amino acid or abbreviation is preceded by the appropriate configuration D (R) o DL (RS).

The compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S M, et al, "Pharmaceutical Salts," J of Pharma Sci 1977;66:1.

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. Preferably, a peptide of Formula I can be converted to an acidic salt by treating with an aqueous solution of the desired acid, such that the resulting pH is less than four. The solution can be passed through a C18 cartridge to absorb the peptide, washed with copious amounts of water, the peptide eluted with a polar organic solvent such as, for example, methanol, acetonitrile, aqueous mixtures thereof, and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloro-procaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S M, et al, "Pharmaceutical Salts," J of Pharma Sci, 1977;66:1.

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. Preferably, a peptide of Formula I can be converted to a base salt by treating with an aqueous solution of the desired base, such that the resulting pH is greater than 9. The solution can be passed through a C18 cartridge to absorb the peptide, washed with copious amounts of water, the peptide eluted with a polar organic solvent such as, for example, methanol, acetonitrile, aqueous mixtures thereof, and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free acid form my be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solrated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.

A preferred compound of Formula I is one wherein ##STR25##

wherein R.sup.3 is hydrogen,

tert-butyloxycarbonyl,

carbobenzyloxy, 9-fluorenylmethyloxycarbonyl,

benzyl,

acetyl, or

phthaloyl,

n is an integer of one to ten,

m is zero or an integer of one or ##STR26## wherein R.sup.5 is hydrogen, or alkyl and

n is as defined above;

His (t-Bu),

His (C(Ph).sub.3),

Tza,

Phe,

Tyr,

Tyr(OMe),

Tyr(Ot-Bu)

1-Nal,

2-Nal,

Pyr,

HomoPhe,

Trp,

Trp(For), or

Trp(Me), or

Ile,

Nle,

Val,

Nva,

Ala,

Chx,

Gly,

Alg,

Cpn, or

Pgy, or

Ash,

Glu,

Gln,

Asp(Ot-Bu),

Asp(OMe),

Glu(Ot-Bu), or

Glu (OMe), or

Leu,

Ile,

Nle,

Val,

Nva,

Ala,

Chx,

Gly,

Alg,

Cpn, or

Pgy, or

Trp(For),

Trp(Me),

His,

Phe,

Tyr(OMe),

Tyr(Ot-Bu),

1-Nal,

2-Nal,

Bta,

Bfa,

Pyr, or

HomoPhe;

Ile-Ile-Trp-NHOH;

Boc-Ile-Ile-Trp-NHOH; ##STR27## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR28## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 4);

Boc-Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 4); ##STR29## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR30## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Leu-Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 6);

Boc-Leu-Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 6); ##STR31## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR32## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

His-Leu-Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 8);

Boc-His-Leu-Asp-Ile-Ile-Trp-NHOH (SEQ ID NO: 8); ##STR33## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR34## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Ile-Ile-Phe-NHOH;

Boc-Ile-Ile-Phe-NHOH; ##STR35## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR36## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Ile-Ile-l-Nal-NHOH;

Boc-Ile-Ile-l-Nal-NHOH; ##STR37## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR38## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Ile-Ile-2-Nal-NHOH;

Boc-Ile-Ile-2-Nal-NHOH; ##STR39## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR40## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Ile-Ile-Bta-NHOH;

Boc-Ile-Ile-Bta-NHOH; ##STR41## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR42## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Ile-Ile-Bfa-NHOH;

Boc-Ile-Ile-Bfa-NHOH; ##STR43## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR44## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Asp-Ile-Ile-Phe-NHOH (SEQ ID NO: 12);

Boc-Asp-Ile-Ile-Phe-NHOH (SEQ ID NO: 12); ##STR45## wherein R is hydrogen,

methyl,

ethyl, or

t-butyl, and

n is an integer of one to ten; ##STR46## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten;

Asp-Ile-Ile-1-Nal-NHOH (SEQ ID NO: 14);

Boc-Asp-Ile-Ile-1-Nal-NHOH (SEQ ID NO: 14); ##STR47## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten; ##STR48## wherein R is hydrogen,

BOC, or

CBZ, and

n is an integer of one to ten;

Asp-Ile-Ile-2-Nal-NHOH (SEQ ID NO: 14);

Boc-Asp-Ile-Ile-2-Nal-NHOH (SEQ ID NO: 14); ##STR49## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten; ##STR50## wherein R is hydrogen,

Boc, or

CBZ, and

n is an integer of one to ten; or a pharmaceutically acceptable salt thereof.

The compounds of Formula I are valuable inhibitors of endothelin converting enzyme. The test employed indicates that the compounds of Formula I possess inhibitory activity towards an endothelin converting enzyme.

ECE Activity Assay: The typical reaction mixture (50 .mu.L) contained 10 .mu.M big ET, 100 mM Hepes-KOH (pH 7.0), 0.25% Triton X-100, 0.01% NaN.sub.3, 0.2 mM phenylmethylsulfonyl fluoride, 50 .mu.M pepstatin A, 0.1 mM leupeptin, the indicated concentration of compound (or DMSO for control), and the indicated amount of protein. The final DMSO concentration was kept at 3%. After incubation for 1.5 hours at 37.degree. C., the reaction was stopped by the addition of EDTA to a final concentration of 10 mM. This final mixture was diluted (usually 100-fold) with the radioimmunoassay buffer (see below) and used for radioimmunoassay.

Radioimmunoassay (RIA): For the measurement of immunoreactive (ir) ET-1, the assay mixture (250 .mu.L) contained the antibody against ET-1, an ET-1 sample, and [.sup.125 I]ET-1 (7000 cpm) in the radioimmunoassay buffer (60 mM potassium phosphate (KPi), pH 7.4/10 mM, EDTA/8 mM, NaN.sub.3 /3% DMSO/0.1% bovine serum albumin/0.1% Tween 20). The order of the addition was ET-1 sample, followed by antibody, then [.sup.125 I]ET-1. After incubation at 4.degree. C. for 0.5 to 2 days, unbound ET-1 was co-precipitated by the addition of charcoal (2.4%, w/v)/dextran (0.24%, w/v) suspension (125 .mu.L) in the RIA buffer with BSA replacedby gelatin (0.25%, w/v). The amount of ir-ET-1 was measured by counting the supernatant and determined from the standard curve. The cross-reactivity to big ET-1 was less than 0.01% and the detection limit was 1 Fmol. ______________________________________ Biological Activity of Compounds of Formula I Exam-                                % ECE ple                           Conc.  Inhi- Number Compound                (.mu.M) bition ______________________________________ 2     BocIleIleTrpNHOH        100    47 3     BocIleIleDTrpNHOH       100    46 4     BocIleTrpNHOH           100    44 6     IleIleTrpNHOH           100    74 ##STR51##               4  20 34 68 10 ##STR52##              IC.sub.50 = 4.7 .mu.M 12 ##STR53##              100    65 13 ##STR54##               10  50 22 57 22    BocAspIleIleTrp(For)-NHOH 10    53 (SEQ ID NO: 4)           40    73 100    87 ______________________________________

An alternative method to prepare compounds of the present invention is described using conventional solid phase peptide chemistry techniques. The linear peptides are prepared by standard solid phase synthetic peptide methodology utilizing a Fmoc/benzyl strategy (Stewart J M, Young J D, Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, Ill., 1984). All protected amino acids and reagents are obtained from commercial sources and are not further purified. The protected peptide resin, such as Sasrin resin, is prepared on an Applied Biosystems 430A Peptide Synthesizer utilizing protocols supplied for a dicyclohexylcarbodiimide-mediated coupling scheme (Standard 1.0, Version 1.4). Amino acid side-chains are protected as follows: Bn(Asp, Glu, Ser, Thr), 2-Cl-Z(Lys), DNP(His), and ACM(Cys). Fmoc deprotection at each step is effected by treatment with piperidine in a suitable solvent such as CH.sub.2 Cl.sub.2. A typical cycle for the coupling of an individual amino acid is illustrated below (reproduced from the ABI manual): Schedule for Solid Phase Peptide Synthesis (use of Fmoc amino acids) Vol     Time Step  Reagent            (mL)    (min) ______________________________________ 1     DCM wash (2 times) 15       3 2     DMF wash (2 times) 15       3 3     Deprotect: DMF:piperidine (1:1) 15      20 4     DMF wash (2 times) 15       3 5     Dioxane:water (2:1) (2 times) 15      10 6     DMF wash (3 times) 15       5 7     DCM wash (3 times) (or DMF) 15       5 8     Symmetrical anhydride of Fmoc 15      15 amino acid in DCM (or DMF:DCM) (use 2 or 3 moles of anhydride) 9     Add 1.0 mL of 10% DIEA in 1       15 DCM                        or until monitoring shows coupling complete 10    Recouple if necessary by   40 repeating Steps 7-9 11    DMF wash (5 times) 15       8 12    iPrOH wash (5 times) 15       8 13    DCM wash (5 times) 15       8 ______________________________________

The peptide is liberated from the solid support using 2% TFA/CH.sub.2 Cl.sub.2. The peptide is treated with benzyloxyamine in the presence of activating agents as described hereinafter under solution peptide synthesis of compounds of Formula I. The benzylhydroxamic derivative and the side-chains are then deprotected under hydrogenation conditions using Pd/BaSO.sub.4 as the catalyst. The crude peptide is purified by reverse phase HPLC.

Thus, the hydroxamate peptides can be prepared on the resin. The hydroxamate peptides are prepared by sequential stepwise coupling of the amino acids selected from R-AA.sup.1, AA.sup.2, AA.sup.3, AA.sup.4, and AA.sup.5 to the preceding amino acid using solid-phase peptide chemistry as described above. The peptide is liberated from the solid support by transesterification with an alcohol such as, for example, methanol, and the like, in the presence of a base such as, for example, triethylamine and the like, to afford a peptide ester of Formula IV NO: 16)                                                   IV

wherein R.sup.12 is alkyl and R, AA.sup.1, AA.sup.2, AA.sup.3, AA.sup.4, and AA.sup.5 are as defined above. The ester of Formula IV is hydrolyzed with a base such as, for example, an alkali metal hydroxide, for example, sodium hydroxide, potassium hydroxide, and the like, to afford an acid of Formula III 16)III

wherein R, AA.sup.1, AA.sup.2, AA.sup.3, AA.sup.4, and AA.sup.5 are as defined above. The acid of Formula III is coupled to a compound of Formula V

wherein AA.sup.6 is as defined above in the presence of a coupling reagent such as, for example, EDAC/HOBt and the like, and a solvent such as, for example, DMF and the like, to afford a compound of Formula II --NH--OBn (SEQ ID NO: 2)                                  II

wherein R, AA.sup.1, AA.sup.2, AA.sup.3, AA.sup.4, AA.sup.5, and AA.sup.6 are as defined above.

A compound of Formula II is hydrogenated in the presence of a catalyst such as, for example, palladium on barium sulfate and the like, and a solvent such as, for example, methanol and the like, to afford after removal of protecting groups by conventional methodology a compound of Formula I.

The compounds of Formula I also may be prepared by conventional solution peptide synthesis. Preferred methods for the preparation of compounds of Formula I are described in Schemes I to VI. ##STR55##

Compounds of Formula I are designated by numbers 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 26, 27, 29, and 30.

These schemes illustrate preferred methods from which a person, skilled in the art, could analogously prepare all compounds of Formula I.

Compounds designated 8 through 11 are prepared as outlined in Scheme I. Thus, Compound 1 is reacted with O-benzylhydroxylamine hydrochloride in the presence of a coupling reagent such as, for example, DCC/HOBt/Et.sub.3 N; EDAC.HCl/Et.sub.3 N, and the like, and a solvent such as, for example, DMF and the like. Alternatively, a conventional mixed anhydride procedure may be used employing methyl, ethyl, or isobutyl chloroformate and a base such as, for example, N-methylpiperidine, morpholine, and the like. The coupling reaction is carried out at about 0.degree. C. to about room temperature for about 3 to about 24 hours to afford the Compound 2. Preferably, the reaction is carried out with DCC/HOBt/Et.sub.3 N in DMF at 0.degree. C. for about 12 to about 15 hours. Compound 2 is treated with an acid such as, for example, TFA, HCl, and the like, in a solvent such as, for example, CH.sub.2 Cl.sub.2 and the like, at about room temperature for about 1 to about 3 hours to afford Compound 3. Preferably, the reaction is carried out with TFA and CH.sub.2 Cl.sub.2 at about room temperature for about 1 hour.

Compound 6 is prepared by reacting Compound 4 with Compound 5 in the presence of an activating agent such as described above, for example, DCC/HOBt, EDAC.HCl/HOBt, and a base, for example, Et.sub.3 N or a mixed anhydride procedure as described above, for example, methyl, ethyl, or isobutyl chloroformate and a base, for example, N-methylpiperidine, morpholine, and the like, in an inert solvent such as, for example, CH.sub.2 Cl.sub.2, CHCl.sub.3, DMF, and the like, at about 0.degree. C. to about room temperature for about 14 hours to afford Compound 6. Preferably, the reaction is carried out with DCC/HOBt and Et.sub.3 N in DMF. The methyl ester of Compound 6 is hydrolyzed with a base such as, for example, an aqueous solution of NaOH, LiOH, KOH, and the like, in a solvent such as, for example, THF, ethanol, methanol, and the like, at about room temperature for about 12 to about 16 hours to afford the acid (Compound 7).

Preferably, the reaction is carried out with 1.1 equivalents of aqueous NaOH in THF at about room temperature for about 12 to about 16 hours. Compound 8 is prepared by reacting Compound 3 with Compound 7 using the coupling conditions used to prepare Compound 6 from Compounds 4 and 5 to afford Compound 8. Compound 8 is hydrogenated at 5 to 50 pounds per square inch (psi) hydrogen in the presence of a catalyst such as, for example, palladium on carbon (5-20%) palladium on barium sulfate (5%), and the like, and a solvent such as, for example, methanol, ethanol, THF, dioxane, and the like, to afford Compound 9. Preferably, the reaction is carried out in the presence of 5% palladium on barium sulfate in methanol. Compound 9 is treated with an acid such as, for example, TFA, HCl, and the like, in a solvent such as, for example, CH.sub.2 Cl.sub.2 and the like, at about room temperature for about 1 to about 3 hours to afford Compound 10. Preferably, the reaction is carried out with TFA at about room temperature for about 1 to about 3 hours. Using the methodology used to convert Compound 9 to Compound 10, one obtains Compound 11 from Compound 8. Compound 11 can be converted to Compound 10 using the methodology used to convert Compound 8 to Compound 9.

Compounds designated 12 to 14 are prepared as outlined in Scheme II. Thus, Compound 11 is reacted with mono-methyl succinate in the presence of an activating agent such as, for example, DCC/HOBt, EDAC.HCl/Et.sub.3 N, and the like, or the mixed anhydride procedure as described above in a solvent such as, for example, DMF and the like at about 0.degree. C. to about room temperature for about 3 hours to about 24 hours to afford Compound 12. Preferably, the reaction is carried out with 1.14 equivalents of mono-methyl succinate and EDAC.HCl/Et.sub.3 N in DMF for 14 hours. The methyl ester of Compound 12 is treated with an aqueous base such as, for example, NaOH, LiOH, KOH, and the like, and a solvent such as, for example, THF, ethanol, methanol, dioxane, and the like, at about room temperature for about 7 days to afford the acid (Compound 13). Preferably, the reaction is carried with 2.2 equivalents of aqueous NaOH and THF at about room temperature for about 7 days. The N-benzyloxyamide of Compound 13 is treated with hydrogen at a pressure of 5 to 50 psi in the presence of a catalyst such as, for example, palladium on barium sulfate (5%) and the like, and a solvent such as, for example, methanol and the like, to afford Compound 14. Preferably, the reaction is carried out in the presence of palladium on barium sulfate and methanol. Alternatively, as outlined in Scheme III, Compound 13 is prepared by reacting Compound 11 with succinic anhydride in a solvent such as, for example, THF, dioxane, DMF, acetonitrile, and the like, to afford Compound 13. Preferably, the reaction is carried out in THF. Compound 13 is treated with hydrogen using the methodology described above to prepare Compound 14.

Compounds designated 15-17 are prepared as outlined in Scheme IV. Thus, Compound 15 is prepared by reacting Compound 11 with N-Boc-11-aminoundecanoic acid using the methodology described above for preparing Compound 6. Preferably, the coupling is carried out in the presence of EDAC/HOBt and pyridine. Compound 16 is prepared by treating Compound 15 with an acid such as, for example, TFA, HCl, and the like, in a solvent such as, for example, CH.sub.2 Cl.sub.2 and the like, at about room temperature for about 1 hour to afford Compound 16. Preferably, the reaction is carried out with TFA in CH.sub.2 Cl.sub.2 at about room temperature for about 1 hour. Compound 17 is prepared by hydrogenating Compound 16 in the presence of a palladium catalyst such as, for example, palladium on barium sulfate (5%) and the like, and a solvent such as, for example, methanol and the like, as described above to afford Compound 17. Preferably, the reaction is carried out in the presence of palladium on barium sulfate (5%) and methanol.

Compounds designated 19 through 20 are prepared as outlined in Scheme V. Thus, Compound 19 is prepared by reacting Compound 4 with Compound 3 using the methodology described above for preparing Compound 6. Preferably, the coupling is carried out in the presence of DCC/HOBt. Compound 20 is prepared by hydrogenating Compound 19 in the presence of palladium catalyst as described in the preparation of Compound 17 from Compound 16.

Compounds designated 22 through 30 are prepared as outlined in Scheme VI. Thus, Compound 21 is reacted with benzyi alcohol in the presence of coupling agents described earlier. Preferably, the reaction is carried out with DCC/DMAP in CH.sub.2 Cl.sub.2 at room temperature for about 10 to 17 hours to afford Compound 22. Compound 22 is treated with an acid such as, for example, TFA, HCl, and the like, in a solvent such as, for example, CH.sub.2 Cl.sub.2, and the like, at about room temperature for about 1 to about 3 hours to afford Compound 23. Compound 23 is reacted with Compound 7 in the presence of coupling agents described earlier. Preferably, the reaction is carried out with DCC/HOBt in DMF at 0.degree. C. to room temperature for about 12 to 16 hours to afford Compound 24.

Compound 24 is hydrogenated at 5 to 50 psi hydrogen in the presence of a palladium catalyst, such as palladium on carbon (20%), and the like, and a solvent such as, for example, methanol, and the like, as described above to afford Compound 25.

Compound 26 is prepared by reacting Compound 25 with O-benzylhydroxylamine hydrochloride in the presence of a coupling agent such as, for example, DCC/HOBt/Et.sub.3 N, EDAC.HCl/Et.sub.3 N, and the like, and a solvent such as, for example, DMF, and the like. The coupling reaction is carried out at about 0.degree. C. to about room temperature for about 3 to about 24 hours. Preferably, the reaction is carried out with DCC/HOBt/Et.sub.3 N in DMF at 0.degree. C. to room temperature for about 12 to about 15 hours. Compound 26 is treated with an acid such as, for example, TFA, HCl, and the like, in a solvent such as, for example, CH.sub.2 Cl.sub.2, and the like, at about room temperature for about 1 to about 3 hours to afford Compound 27. Preferably, the reaction is carried out with TFA and CH.sub.2 Cl.sub.2 at about room temperature for about 1 hour.

Compound 29 is prepared by reactinS Compound 27 with Compound 28 in the presence of an activating agent such as described above, for example, DCC/HOBt, EDAC.HCl/HOBt, and a base, for example, Et.sub.3 N or a mixed anhydride procedure as described above in a solvent such as, for example, DMF, and the like, at about 0.degree. C. to about room temperature for about 3 hours to about 24 hours. Preferably, the reaction is carried out with DCC/HOBt in DMF for 14 hours. The N-benzyloxyamide of Compound 29 is treated with hydrogen at a pressure of 5 to 50 psi in the presence of a catalyst such as, for example, palladium on barium sulfate (5%), and the like, and a solvent such as, for example, methanol to afford Compound 30.

All the hydroxamate compounds of Formula I can be prepared by the methods outlined in Schemes I to VI.

The strategy of peptide chain assembly and removal of protecting groups is discussed in Chapter 1, "The Peptide Bond," in "The Peptides. Analysis, Synthesis, Biology," Gross E, Meienhofer J, Eds., Academic Press, New York, N.Y. 1979;1:42.

The DCC/HOBt method of coupling is well known to those skilled in the art and is discussed in Chapter 5, "The Carbodiimide Method" by Rich D H, Singh J, in "The Peptides. Analysis, Synthesis, Biology," Gross E, Meienhofer J, Eds., Academic Press, New York, N.Y. 1979;1:241.

Peptide coupling depends on activating the carboxyl group of the protected amino acid prior to condensing it with another peptide containing a free amino terminus. In addition to the DCC coupling method described above, other methods of activating the carboxyl group of a protected amino acid include:

1) The azide method--described in Chapter 4 of the above reference.

2) The mixed anhydride method--described in Chapter 6 of the above reference.

3) The active ester method--described in Chapter 3 of the above reference.

The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from 5% or 10% to about 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 200 mg preferably 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use inhibitors of endothelin converting enzyme the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 500 mg/kg daily. A daily dose range of about 0.01 mg to about 100 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The following nonlimiting example illustrates the inventors' preferred methods for preparing the compounds of the invention. carbonyl]-L-isoleucyl-L-isoleucyl-N-(phenylmethoxy)-L-tryptophanamide) (methyl-N-[N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl]-L-isoleucine)

A solution of N-Boc-L-isoleucine hemihydrate (26.44 g, 0.11 mol), L-isoleucine methyl ester hydrochloride (20.0 g, 0.11 mol), and HOBt (18.42 g, 0.132 mol) in DMF (300 mL) is treated with triethylamine (37.58 mL, 0.276 mol), followed by DCC (26.08 g, 0.122 mol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for a total of 21 hours. The suspension is filtered and the filtrate is concentrated. The residue is treated with EtOAc and the solution filtered. The filtrate is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over Na.sub.2 SO.sub.4, and concentrated. The crude product is suspended in boiling hexane and EtOAc is added portionwise until the solution is homogeneous. The solution is filtered hot, and upon cooling to 0.degree. C., 31.79 g of the title compound is obtained as a white crystalline solid; Mass spectroscopy (chemical ionization) (MS(CI)), M+1=359 BOc-Ile-Ile([N-[(1,1-dimethyl-ethoxy)carbonyl]-L-isoleucyl]-L-isoleucine)

A solution of Boc-Ile-Ile-OCH.sub.3 (5.0 g, 0.014 mol) in THF (50 mL) is treated dropwise with aqueous 1N NaOH (15 mL, 0.015 mol). After addition is complete the reaction mixture is stirred at room temperature for 16 hours and concentrated. The residue is dissolved in water and the aqueous solution is extracted with diethyl ether. The organic layer is discarded and the pH of the aqueous layer is adjusted to 2 to 3 with aqueous 1N citric acid. The acidic solution is extracted with EtOAc and the organic extract is washed with saturated aqueous NaCl, dried over Na.sub.2 SO.sub.4, filtered, and concentrated to give 4.65 g of the title compound as a white foam; MS(CI), M+1=345. Boc-Trp-NHOBn(1,1-dimethyl-ethyl(S)-1-(1H-indol-3-ylmethyl)-2-oxo-2-[(phen ylmethoxy)amino]carbamate)

A solution of N-.alpha.-t-butoxycarbonyl-L-tryptophan (12.0 g, 0.0396 mol), O-benzylhydroxylamine hydrochloride (6.32 g, 0.0396 mol), and HOBt (6.42 g, 0.0475 mol) in DMF (120 mL) is treated with triethylamine (13.8 mL, 0.0992 mol) followed by DCC (9.0 g, 0.0436 mol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for 22 hours. The suspension is filtered and the filtrate is concentrated. The residue is treated with EtOAc and filtered. The filtrate is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over Na.sub.2 SO.sub.4, filtered, and concentrated. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 4% methanol in chloroform) to afford 10.75 g of the title compound as a white foam; MS(CI), M+1=410. Trp-NHOBn((S)-.alpha.-amino-N-(phenylmethoxy)-1H-indole-3-propanamide)

To a solution of Boc-Trp-NHOBn (3.48 g, 8.5 mmol) in dichloromethane (35 mL), is added portionwise trifluoroacetic acid (35 mL, 0.45 mol) at 0.degree. C. with vigorous stirring. After addition of acid is complete the reaction mixture is stirred at room temperature for 1 hour and concentrated. The residue is taken up in EtOAc (50 mL) and the organic layer is cautiously washed with saturated aqueous NaHCO.sub.3 until neutral. The organic layer is washed with saturated aqueous NaCl, dried over Na.sub.2 SO.sub.4, and concentrated to afford 2.37 g of the title compound as a light yellow foam; MS(CI), M+1=310. Trp-NHOBn.HCl((S)-.alpha.-amino-N-(phenylmethoxy)-1H-indole-3-propanamide, hydrochloride)

Hydrogen chloride gas is bubbled into a solution of BOC Trp-NHOBn (2.04 g, 5.0 mmol) in chloroform (100 mL) for 5 minutes at room temperature. The solution is stirred for 1 hour and concentrated to give 1.73 g of the title compound as an off-white solid; MS(CI), M+1=310. Boc-Ile-Ile-Trp-NH-OBn(N-[1,1-dimethylethoxy)carbonyl]-L-isoleucyl-L-isole ucyl-N-(phenylmethoxy)-L-tryptophanamide)

A solution of Boc-Ile-Ile (2.65 g, 7.7 mol) with Trp-NHOBn (2.37 g, 7.7 mmol), and HOBt (1.25 g, 9.2 mmol) in DMF (50 mL) is treated with N-methyl-piperidine (1.10 mL), 9.2 mmol) followed by EDAC.HCl (1.76 g, 9.2 mmol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for 15 hours. The solution is concentrated and the residue is partitioned between EtOAc and water. The bilayer is stirred at 0.degree. C. for 2 hours. The precipitate is filtered and washed with water, diethyl ether, and a small amount of chloroform to afford 2.08 g of the title compound; MS fast atom bombardment (FAB), M+1=636. yl-N-hydroxy-L-tryptophanamide)

A suspension of Boc-Ile-Ile-Trp NHOBn (Example 1) (0.76 g, 1.2 mmol) and Pd/BaSO.sub.4 (5%, 0.60 g) in methanol (75 mL) is hydrogenated (53.4 psi) for 23 hours. TLC (SiO.sub.2 ; CHCl.sub.3 :MeOH, 9:1) shows complete reaction of starting material. The reaction mixture is filtered through celite and the filtrate is concentrated. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, chloroform:methanol 9:1) to afford 0.55 g of the title compound as a light orange, amorphous solid; MS(FAB), M+Na=568.

In a process analogous to Examples 1 and 2 using appropriate starting materials, the corresponding compounds of Formula I are prepared as follows: carbonyl]-L-isoleucyl-L-isoleuyl-N-hydroxy-D-tryptophanamide); MS(CI), M - CONHOH=485. carbonyl]-L-isoleucyl-N-hydroxy-L-tryptophanamide); MS(CI), M - CONHOH=372. e)

To a suspension of Boc-Ile-Ile-Trp-NHOBn (Example 1) (1.50 g, 2.4 mmol) in dichloromethane (20 mL) is added portionwise trifluoroacetic acid (20 mL, 0.26 mol) at 0.degree. C. with vigorous stirring. After addition is complete the reaction mixture is stirred at room temperature for 1 hour and concentrated. The residue is mixed with EtOAc and the organic layer is washed with saturated aqueous NaHCO.sub.3. Upon neutralization of the excess acid, the product begins to precipitate in the organic layer. The organic suspension is diluted with diethyl ether and chilled at 0.degree. C. for 1 hour. The title compound, 1.15 g, is collected as a light orange, amorphous solid; MS(CI), M+1=536. monohydrochloride)

Hydrogen chloride gas is bubbled into a partial suspension of N-[(1,1-dimethylethoxy) carbonyl]-L-isoleucyl-L-isoleucyl-N-hydroxy-L-tryptophanamide (Example 2) (200 mg, 3.67.times.10.sup.-4 mol) in chloroform (60 mL) for 5 minutes at room temperature. Upon the introduction of gas, all solid goes into solution and throughout the bubbling period a precipitate forms. After 1 hour the solution is concentrated to give 140 mg of the title compound as a pinkish-white amorphous solid; MS(FAB), M+1=446.2. ##STR56##

A solution of monomethyl succinate (0.32 g, 2.4 mmol) with Ile-Ile-Trp-NHOBn (Example 5) (1.15 g, 2.1 mmol), and HOBt (0.39 g, 2.9 mmol) in DMF (15 mL) is treated with N-methylpiperidine (0.35 mL, 2.9 mmol), followed by EDAC.HCl (0.55 g, 2.9 mmol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for 14 hours. The reaction mixture is concentrated and the residue partitioned between EtOAc and water. After stirring for 30 minutes the product precipitates as a light yellow, amorphous solid which is washed with water and EtOAc and on filtration affords 0.87 g of the title compound; MS(FAB), M+1=650. ##STR57##

A solution of N-(4-methoxy-1,4-dioxobutyl)-L-isoleucyl-L-isoleucyl-N-(phenylmethoxy)-L-t ryptophanamide (Example 7) (0.87 g, 1.3 mmol) and Pd/BaSO.sub.4 catalyst (5%, 0.10 g) in MeOH (75 mL) is hydrogenated for 19 hours (52.6 psi). A precipitate forms during the course of the reaction and is dissolved upon addition of DMF. TLC (SiO.sub.2, chloroform:MeOH 9:1) shows complete reaction of starting material. The catalyst is filtered using celite and the filtrate is concentrated. The residue is taken up in boiling MeOH and is refrigerated for 24 hours to precipitate 250 mg of the title compound; MS(FAB), M+Na=536.4. ##STR58##

A suspension of methyl ester ##STR59## (Example 7) (0.59 g, 9.08.times.10.sup.-4 mol). in methanol (10 mL) is treated with aqueous 1N NaOH (1.0 mL, 1.0.times.10.sup.-4 mol). The resulting solution is stirred at room temperature for 6 days after which time an additional amount of aqueous 1N NaOH (1.0 mL, 1.0.times.10.sup.-4 mol) is added and stirring continued for another 22 hours. The reaction mixture is concentrated and the residue is dissolved in water. The aqueous layer is extracted with Et0Ac and the organic layer is discarded. The aqueous layer is filtered through celite and acidified to pH=2 with aqueous IN HCl. The free acid precipitates as a gel and is washed with water and EtOAc and upon collection affords 0.41 g of the title compound; MS (FAB), M+1=636.4. ##STR60##

A suspension of ##STR61## (Example 9) (0.32 g, 5.03.times.10.sup.-4 mol) and Pd/BaSO.sub.4 (5%, 0.10 g) in methanol (75 mL) is hydrogenated (50.8 psi) for 18 hours. TLC (SiO.sub.2 ; CHCl.sub.3 : MeOH, 9:1) shows complete reaction of starting material. The reaction mixture is filtered through celite and the filtrate is concentrated. The solid residue is suspended in hot, HPLC grade water and methanol is added dropwise until all remaining solids went into solution. The solution is filtered hot and the hydroxamate precipitates upon cooling. The light orange solid is collected and washed with HPLC grade water to afford 0.19 g of the title compound; MS(FAB), M+Na=568.4. ##STR62## Step 1: Preparation of ##STR63##

A suspension of 11-aminoundecanoic acid (7.0 g, 0.035 mol), di-tert-butyl dicarbonate (8.45 g, 0.039 mol), and triethylamine (5.30 mL, 0.039 mol) in methanol (100 mL) is stirred at room temperature under nitrogen atmosphere for 20 hours. The resultant solution is concentrated and the residue is partitioned between water and diethyl ether. The aqueous layer is washed with diethyl ether and acidified to pH=2 with aqueous 1N HCl. The acid layer is extracted with EtOAc and the organic extract dried over MgSO.sub.4, filtered, and concentrated to afford 7.59 g of the title compound as a white, amorphous solid; MS(CI), M+1=302. Ile-Ile-OCH.sub.3.HCl(methyl-N-L-isoleucyl-L-isoleucine, monohydrochloride)

Hydrogen chloride gas is bubbled into a solution of Boc-Ile-Ile-OCH.sub.3 (Example 1, Step 1) (3.0 g, 8.4 mmol) in chloroform (100 mL) for 5 minutes at room temperature. After stirring for an additional 1 hour the solution is concentrated to afford 2.48 g of the title compound as a white, amorphous solid; MS(CI), M+1=259. ##STR64##

A mixture of ##STR65## (2.68 g, 8.9 mmol), Ile-Ile-OCH.sub.3.HCl (2.62 g, 8.9 mmol), and HOBt (1.44 g, 10.7 mmol) in DMF (50 mL) is treated with triethylamine (3.02 mL, 2.19 g, 22.2 mmol) followed by DCC (2.02 g, 9.8 mmol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and allowed to warm up to room temperature over a period of 15 hours. The resulting suspension is filtered and the filtrate is concentrated. The residue is mixed with ethyl acetate and the solution is filtered. The filtrate is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over Na.sub.2 SO.sub.4, filtered, and concentrated. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, hexane:EtOAc, 7:3 to 3:2) to give 3.68 g of the title compound as a clear, viscous foil; MS(CI), M=541. ##STR66## sodium salt (N-[11-[[(1,1-dimethylethoxy)carbonyl]-amino]1-oxoundecanyl]-L-isoleucyl]- L-isoleucine, monosodium salt)

A solution of ##STR67## (3.58 g, 6.6 mmol) in methanol (40 mL) is treated portionwise with aqueous 1N NaOH (7.3 mL, 7.3 mmol). After addition is complete, the reaction mixture is stirred at room temperature for 5 days. An insoluble residue is removed by filtration and the filtrate is concentrated to afford 3.70 g of the title compound as a white foam. ##STR68##

A solution of ##STR69## sodium salt (3.70 g, 6.7 mmol), Trp-NHOBn (Example 1, Step 4) (2.27 g, 7.3 mmol), and HOBt (1.08 g, 8.0 mmol) in DMF (60 mL) is treated with N-methylpiperidine (1.62 mL, 13.4 mmol) and EDAC-HCl (1.54 g, 8.0 mmol) at 0.degree. C. The reaction mixture is kept cold for 2 to 3 hours and allowed to warm to room temperature over 19 hours. The reaction mixture is concentrated and the residue is partitioned between EtOAc and saturated aqueous NaHCO.sub.3. The bilayer is vigorously stirred for 1 hour at 0.degree. C., and the white precipitate which forms, is filtered and washed with water, EtOAc, and a small amount of methanol to afford 4.70 g of the title compound; MS(FAB), M+Na=841.7. ##STR70##

To a suspension of ##STR71## (Example 11) (SEQ ID NO: 3) (1.14 g, 1.4 mmol) in dichloromethane (50 mL) is added dropwise trifluoroacetic acid (30 mL, 0.39 mol) at 0.degree. C. After the addition of acid, a homogeneous solution is obtained. The reaction mixture is stirred at room temperature for 1 hour and concentrated. The residue is partitioned between EtOAc and saturated aqueous NaHCO.sub.3. A white solid (1.27 g) precipitates and is suspended in boiling water. Methanol is added dropwise until homogeneous. The solution is filtered hot and upon cooling 0.42 g of the title compound precipitates as a white, amorphous solid; MS(FAB), M+1=719.6. ##STR72##

A suspension of ##STR73## (Example 12) (SEQ ID NO: 3) (200 mg, 0.28 mmol) and Pd/BaSO.sub.4 (5%, 0.1 g) in methanol (75 mL) is hydrogenated (52.3 psi) for 15 hours. TLC (SiO.sub.2 ; CHCl.sub.3 : MeOH, 9:1) shows complete loss of starting material. The reaction mixture is filtered through celite and the filtrate is concentrated to give the title compound as a white solid (122 mg). The catalyst is suspended in boiling methanol and filtered through celite. The filtrate is concentrated to a solid (35 mg) which had identical analytical data with the initial product isolated; MS(FAB), M+1=629. hoxy)-L-tryptophanamide)

A solution of Boc-Ile (0.74 g, 3.2 mmol) and Trp-NHOBn (Example 1, Step 4) (0.98 g, 3.2 mmol) in DMF (20 mL) cooled to 0.degree. C. is treated with HOBt (0.51 g, 3.8 mmol), followed by DCC (0.72 g, 3.5 mmol). The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for a total of 13 hours. The reaction mixture is filtered and the filtrate is concentrated. The residue is treated with EtOAc and the solution is filtered. The filtrate is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over Na.sub.2 SO.sub.4, and concentrated. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 4% methanol in chloroform) to give 0.76 g of the title compound as a yellow foam; MS(CI), M+1=523. ryptophan)

To a solution of N-.alpha.-Boc-N-indoleformyltryptophan (3.99 g, 0.0126 mmol), benzyl alcohol (1.33 mL, 0.0129 mmol), and 4-dimethylaminopyridine (DMAP, 0.30 g, 2.6 mmol) in methylene chloride (70 mL) is added DCC (2.54 g, 0.0126 mol). The reaction mixture is stirred under nitrogen at room temperature for 17 hours after which time the precipitated urea is filtered and the filtrate is concentrated. The residue is taken up in EtOAc and refiltered. The filtrate is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over MgSO.sub.4, filtered, and concentrated. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 7:3 hexane:EtOAc) to give 4.25 g of the title compound as a white, crystalline solid which is washed with hexane upon collection; MS(CI), M+1=422.

The Boc group of Boc-Trp(For)OBn (6.60 g, 0.016 mol) is removed using the procedure described in Example 1, Step 4, to give 4.80 g of the title compound. -L-isoleucyl]-L-isoleucyl]-1-formyl-L-tryptophan)

A solution of Boc-Ile-Ile (4.64 g, 0,013 mol), Trp(For)OBn (Example 14) (4.34 g, 0.013 mol), and HOBt (2.23 g, 0.016 mol) in DMF (80 mL) cooled to 0.degree. C. is treated with DCC (2.99 g, 0.014 mol). The reaction mixture is kept cold for 2 to 3 hours and stirred at room temperature for 16 hours. The reaction mixture is filtered and the filtrate is concentrated. The residue was taken up in warm EtOAc and the organic layer is washed with saturated aqueous solutions of NaHCO.sub.3 and NaCl, dried over MgSO.sub.4, filtered, and concentrated (upon cooling of the organic layer a small amount of product precipitation is observed). The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 7:3 hexane:EtOAc to 3:2 hexane:EtOAc) to give 3.92 g of the title compound as a white solid; MS(CI), M+1=649. -L-isoleucyl]-1-formyl-L-tryptophan)

A solution of Boc-Ile-Ile-Trp(For)OBn (Example 17) (1.50 g, 2.3 mmol) and Pd/C (20%, 1.0 g) in methanol (100 mL) is hydrogenated (50 psi) for 2 hours. TLC (SiO.sub.2 ; hexane:EtOAc 1:1) shows complete loss of starting material. The reaction mixture is filtered through celite and the filtrate is concentrated to give 1.28 g of the title compound; MS (CI), M+1=559. soleucyl-1-formyl-N-(phenyl-methoxy)-L-tryphophanamide)

Boc-Ile-Ile-Trp (For) OH (Example 18) (1.27 g, 2.3 mmol) is coupled with O-benzylhydroxylamine hydrochloride (0.37 g, 2.3 mmol) using the procedure described in Example 1, Step 3. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 4% methanol in chloroform) to give 0.99 g of the title compound as an orange, amorphous solid; MS(FAB) M+1=664. tryptophanamide)

The Boc group of Boc-Ile-Ile-Trp(For)NHOBn (Example 19) (0.95 g, 1.5 mmol) is removed using the procedure described in Example 10 to give 0.64 g of the title compound as a white solid. bonyl]-L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-1-formyl-N-(phenylmethoxy )-L-tryptophanamide) (SEQ ID NO: 4)

Ile-Ile-Trp(For)NHOBn (Example 20) (0.64 g, 1.1 mmol) is coupled with Boc-aspartic acid-.beta.-benzyl ester (0.36 g, 1.1 mmol) according to the procedure described in Example 15. The crude product is purified by flash chromatography (silica gel 60, 230-400 mesh, 3% methanol in chloroform) to give 0.69 g of the title compound as an orange foam; MS (FAB), M+Na+H=893. (N-[(1,1-dimethylethoxy)-carbonyl]-L-.alpha.-aspartyl-L-isoleucyl-n-isoleu cyl-1-formyl-N-hydroxy-n-tryptophanamide) (SEQ ID NO: 4)

Boc-Asp (OBn)-Ile-Ile-Trp(For)NHOBn (Example 21) (SEQ ID NO: 4) (0.65 g, 7.5.times.10.sup.-4 mmol) is hydrogenated according to the procedure described in Example 8 to give 0.51 g of the title compound as a light orange foam; MS (FAB), M+Na+H.sub.2 =713. SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 16 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: XaaXaaXaaXaaXaa 15 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: XaaXaaXaaXaaXaaXaaXaa 15 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: XaaIleIleTrp (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: AspIleIleTrp 1 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: XaaAspIleIleTrp 15 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: LeuAspIleIleTrp 15 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: XaaLeuAspIleIleTrp 15 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: HisLeuAspIleIleTrp 15 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: XaaHisLeuAspIleIleTrp 15 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: XaaIleIlePhe 1 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: XaaIleIleXaa 1 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: AspIleIlePhe 1 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: XaaAspIleIlePhe 15 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AspIleIleXaa 1 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: XaaAspIleIleXaa 15 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: XaaXaaXaaXaaXaaXaa 15 __________________________________________________________________________

## Claims

1. A compound of Formula I ##STR74## wherein R is hydrogen, ##STR75## wherein R.sup.3 is hydrogen, tert-butyloxycarbonyl, carbobenzyloxy, 9-fluorenylmethyloxycarbonyl, benzyl, acetyl, or phthaloyl, ##STR76## wherein R.sup.5 is hydrogen or alkyl, and n is as defined above; thereof.

2. A compound according to claim 1 selected from the group consisting of ##STR77## wherein R is hydrogen, methyl, ##STR78## wherein R is hydrogen, Boc, or ##STR79## wherein R is hydrogen, methyl, ##STR80## wherein R is hydrogen, Boc, or ##STR81## wherein R is hydrogen, methyl, ##STR82## wherein R is hydrogen, BOC, or ##STR83## wherein R is hydrogen, methyl, ##STR84## wherein R is hydrogen, Boc, or ##STR85## wherein R is hydrogen, methyl, ##STR86## wherein R is hydrogen, Boc, or ##STR87## wherein R is hydrogen, methyl, ##STR88## wherein R is hydrogen, Boc, or ##STR89## wherein R is hydrogen, methyl, ##STR90## wherein R is hydrogen, Boc, or ##STR91## wherein R is hydrogen, methyl, ##STR92## wherein R is hydrogen, Boc, or ##STR93## wherein R is hydrogen, Boc, or ##STR94## wherein R is hydrogen, Boc, or ##STR95## wherein R is hydrogen, Boc, or ##STR96## wherein R is hydrogen, Boc, or

3. A method of treating hypertension comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

4. A method of treating congestive heart failure and myocardial infarction comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

5. A method of treating asthma comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

6. A method of treating acute renal failure comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

7. A method of treating pulmonary hypertension comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

8. A method of treating cerebral vasospasm comprising administering to a mammal suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 7 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

10. A pharmaceutical composition adapted for administration as an inhibitor of endothelin converting enzyme, as an antihypertensive agent, as an agent for treating congestive heart failure and myocardial infarction, as an agent for treating subarachnoid hemorrhage, as an agent for treating asthma, as an agent for treating acute renal failure, as an agent for treating pulmonary hypertension, as or as an agent for treating cerebral vasospasm comprising a therapeutically effective amount of a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

11. A mixture of two or more compounds according to claim 1, wherein in the said mixture the stereochemistry of any of AA.sup.3, AA.sup.4, AA.sup.5 and AA.sup.6 is L, D or DL.